Repligen 

$130.87
31
+$0.28+0.21% Today

Statistics

Day High
134.59
Day Low
130.42
52W High
175.77
52W Low
100.99
Volume
562,114
Avg. Volume
1,082,309
Mkt Cap
7.37B
P/E Ratio
134.76
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
0.34
0.38
0.43
0.48
Expected EPS
0.453312
Actual EPS
N/A

Financials

6.62%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.48BRevenue
97.79MNet Income

Analyst Ratings

165.80Average Price Target
The highest estimate is 208.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
10%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGEN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Danaher
DHR
Mkt Cap127.47B
Danaher Corporation operates in the life sciences field, offering products and services similar to Repligen's bioprocessing technologies, making them direct competitors in the biotech and pharmaceutical manufacturing sector.
Thermo Fisher Scientific
TMO
Mkt Cap174.42B
Thermo Fisher Scientific provides a range of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics, overlapping with Repligen's offerings in bioprocessing and biomanufacturing.
Bio-Rad Laboratories
BIO
Mkt Cap7.65B
Bio-Rad Laboratories offers products and services in the field of life science research and clinical diagnostics, competing with Repligen in the supply of bioprocessing equipment and consumables.
Sartorius
SARTF
Mkt Cap15.03B
Sartorius AG competes with Repligen in the bioprocessing market, offering similar bioprocess solutions including filters and single-use systems for the biopharmaceutical industry.
Illumina
ILMN
Mkt Cap24.35B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which, while more focused on genomics, competes with Repligen in the broader biotech research and development space.
Casey`s General Stores
CASY
Mkt Cap33.18B
Catalent, Inc. offers delivery technologies and development solutions for drugs, biologics, and consumer health products, competing with Repligen in the biomanufacturing and bioprocessing sectors.
Avantor
AVTR
Mkt Cap6.25B
Avantor, Inc. provides products and services to the life sciences and advanced technology industries, competing with Repligen in the supply of materials and consumables for bioprocessing.
Repligen
RGEN
Mkt Cap7.07B
Regeneron Pharmaceuticals, while primarily a biotechnology company focused on developing and commercializing pharmaceuticals, competes with Repligen through its demand and innovation in bioprocessing technologies for drug development.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc., as a biopharmaceutical company, indirectly competes with Repligen by developing bioprocessing technologies in-house for their drug development, representing competition for market share in bioprocessing solutions.
GE HealthCare Technologies
GEHC
Mkt Cap29.65B
GE Healthcare provides medical technology and digital solutions, including bioprocessing technologies that compete with Repligen's offerings in the life sciences and biopharmaceutical manufacturing sectors.

About

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Show more...
CEO
Mr. Olivier Loeillot
Employees
1778
Country
United States
ISIN
US7599161095

Listings

0 Comments

Share your thoughts

FAQ

What is Repligen stock price today?
The current price of RGEN is $130.87 USD — it has increased by +0.21% in the past 24 hours. Watch Repligen stock price performance more closely on the chart.
What is Repligen stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Repligen stocks are traded under the ticker RGEN.
Is Repligen stock price growing?
RGEN stock has risen by +4.42% compared to the previous week, the month change is a +27.22% rise, over the last year Repligen has showed a +2.63% increase.
What is Repligen market cap?
Today Repligen has the market capitalization of 7.37B
When is the next Repligen earnings date?
Repligen is going to release the next earnings report on August 04, 2026.
What were Repligen earnings last quarter?
RGEN earnings for the last quarter are 0.48 USD per share, whereas the estimation was 0.38 USD resulting in a +24.97% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Repligen revenue for the last year?
Repligen revenue for the last year amounts to 1.48B USD.
What is Repligen net income for the last year?
RGEN net income for the last year is 97.79M USD.
How many employees does Repligen have?
As of June 15, 2026, the company has 1,778 employees.
In which sector is Repligen located?
Repligen operates in the Health & Wellness sector.
When did Repligen complete a stock split?
Repligen has not had any recent stock splits.
Where is Repligen headquartered?
Repligen is headquartered in Waltham, United States.